Department of Medicine
Lilly Research Laboratories
United States Minor Outlying Islands
Dr. Zamek-Gliszczynski is currently working as a Professor in the Department of Medicine, Lilly Research Laboratories , USA. His research interests includes Medicine. He /she is serving as an editorial member and reviewer of several international reputed journals. Dr. Zamek-Gliszczynski is the member of many international affiliations. He/ She has successfully completed his Administrative responsibilities. He /she has authored of many research articles/books related to Medicine.
Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Clin Pharmacol Ther. 2014 May;95(5):473-6.
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein. Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, Zamek-Gliszczynski MJ. Drug Metab Dispos. 2014 Jan;42(1):182-92.
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Drug Metab Dispos. 2012 Jun;40(6):1170-7.